Abstract

BackgroundThe greatest impediment to effective malaria control is drug resistance in Plasmodium falciparum, and thus understanding how resistance impacts on the parasite's fitness and pathogenicity may aid in malaria control strategy.Methodology/Principal FindingsTo generate resistance, P. berghei NK65 was subjected to 5-fluoroorotate (FOA, an inhibitor of thymidylate synthase, TS) pressure in mice. After 15 generations of drug pressure, the 2% DT (the delay time for proliferation of parasites to 2% parasitaemia, relative to untreated wild-type controls) reduced from 8 days to 4, equalling the controls. Drug sensitivity studies confirmed that FOA-resistance was stable. During serial passaging in the absence of drug, resistant parasite maintained low growth rates (parasitaemia, 15.5%±2.9, 7 dpi) relative to the wild-type (45.6%±8.4), translating into resistance cost of fitness of 66.0%. The resistant parasite showed an apoptosis-like death, as confirmed by light and transmission electron microscopy and corroborated by oligonucleosomal DNA fragmentation.Conclusions/SignificanceThe resistant parasite was less fit than the wild-type, which implies that in the absence of drug pressure in the field, the wild-type alleles may expand and allow drugs withdrawn due to resistance to be reintroduced. FOA resistance led to depleted dTTP pools, causing thymineless parasite death via apoptosis. This supports the tenet that unicellular eukaryotes, like metazoans, also undergo apoptosis. This is the first report where resistance to a chemical stimulus and not the stimulus itself is shown to induce apoptosis in a unicellular parasite. This finding is relevant in cancer therapy, since thymineless cell death induced by resistance to TS-inhibitors can further be optimized via inhibition of pyrimidine salvage enzymes, thus providing a synergistic impact. We conclude that since apoptosis is a process that can be pharmacologically modulated, the parasite's apoptotic machinery may be exploited as a novel drug target in malaria and other protozoan diseases of medical importance.

Highlights

  • Malaria, caused by protozoan parasite of the genus Plasmodium is the most widespread parasitic disease, with malaria endemic regions encompassing approximately 40% of the global human population

  • FOA-resistance is readily generated in 100 asexual cycles Figure 1 shows 2% delay time’ (2% DT) of parasites subjected to FOA

  • Parasites subjected to PYR over 12 serial passages (93 days, 93–101 asexual cycles) showed no change in 2% DT, which remained constant at 8 days

Read more

Summary

Introduction

Malaria, caused by protozoan parasite of the genus Plasmodium is the most widespread parasitic disease, with malaria endemic regions encompassing approximately 40% of the global human population. Whereas the rising incidence in malaria morbidity and mortality is largely associated with drug failure following resistance, it is possible that resistance induces an alteration of the intrinsic parasite traits that may influence parasite fitness (growth and multiplication) and virulence (harm to the host following infection), impacting on malaria mortality and morbidity [3,4]. The greatest impediment to effective malaria control is drug resistance in Plasmodium falciparum, and understanding how resistance impacts on the parasite’s fitness and pathogenicity may aid in malaria control strategy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call